Innovation is accelerating progress in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to si...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Top 10 factors to design and deploy a decentralised clinical trial
Dr. Isaac Rodriguez-Chavez considers the top 10 factors when designing and deploying a decentralised clinical trial.
This article is taken from International Clinical Trials August 2021, pages 8-10. Samedan Ltd.
-
Pharma’s coming home
Seth Nelson, Senior Director of Patient Recruitment and Clinical Research Services, provides expert commentary on patient centricity during the pandemic.
-
Ensuring better patient outcomes through decentralised & hybrid trials
ICON CEO Steve Cutler discusses how the research industry has changed in the past year, concluding that decentralised models are helping to improve patient outcomes and bring treatments to market faster (page 12).
-
Practical considerations when deploying a decentralised or hybrid clinical trial
A discussion around the key components of decentralised trials and steps of deployment.
-
Pfizer COVID vaccine trial proved remote monitoring, other innovations work, ICON CEO says
ICON CEO Steve Cutler discusses how the Pfizer COVID vaccine trial proves that starting clinical trials in weeks, as opposed to months, should be possible post-pandemic.
-
Decentralised & hybrid trials: The future of clinical trials post pandemic
An interview with EB McLindon, Senior VP, Patient, Site & Decentralised Solutions, on why the future of drug development involves decentralising parts of the clinical trial process.
-
ICON talks about the inclusivity of decentralised trials
Patients as Partners Autumn newsletter (pages 14 & 15) features a Q&A with EB McLindon, Senior VP, Site, Patient and Decentralised Solutions, on the inclusivity of decentralised clinical trials.
-
Clinical trials shift to hybrid approaches in the age of COVID-19 and beyond
An article examining the state of clinical trials for orthopedics, featuring expert commentary from ICON's David T. Novotny, General Manager & Global Head, Medical Device & Diagnostic Research.
-
Patient centricity: Exploring the patient perspective from different angles
An article exploring the challenges and potential solutions of integrating patient insight for improved outcomes from the perspective of a patient advocate, clinical investigator and pharmaceutical executive.
-
AI in Life Sciences – Covid pushes AI driven clinical trials and drug manufacturing into the limelight
ICON’s CIO, Tom Leary discusses the challenges to patient recruitment during the COVID pandemic and how big data, combined with advanced AI algorithms processing has the potential to reduce trial costs.
